Skip to main content
Home
  • Company
    • History
    • Leadership
    • Clients and Collaborators
    • By the Numbers
  • Capabilities
    • Emmes - CRO
      • Specialties
        • Vaccines & Infectious Diseases
        • Ophthalmology
        • Clinical Neuroscience
        • Rare Disease
        • Cell & Gene Therapy
        • Government
      • Additional Specialties
        • Hematology
        • Oncology
        • Maternal & Child Health
        • Medical Devices
      • Clinical Services
        • Biostatistics
        • Clinical Data Management
        • Clinical Research Services
        • Clinical Trial Management
        • Global Regulatory Affairs
        • Pharmacovigilance & Medical Monitoring
    • Veridix - Tech & AI
      • eClinical Platform
        • EDC
        • Decentralized Clinical Trials
        • Health Navigator
        • RTSM
        • eCOA / ePRO
      • AI Agents
        • Biostats and Analysis Agent
        • Data Management Agent
        • Document Authoring
      • GlobalTrace
      • Analytics & Reporting
        • Clinical Pipelines
        • VERA
  • Resources
    • Newsroom
    • Blog
  • Careers
  • Contact
    • Locations
    • Contact Us

Breadcrumb

  1. Emmes Group

A Phase 2 Study to Evaluate the Safety and Immunogenicity of a Recombinant Adeno-Associated Virus HIV Vaccine

Go back to Resources

A Phase 2 Study to Evaluate the Safety and Immunogenicity of a Recombinant Adeno-Associated Virus HIV Vaccine

Authors:

Secondary:

Location:

URL:

Go back to Resources

Younger Age and Antibody Induction Increase the Risk for Infection in Pediatric Renal Transplantation: A NAPRTCS Report

Go back to Resources

Younger Age and Antibody Induction Increase the Risk for Infection in Pediatric Renal Transplantation: A NAPRTCS Report

Authors:

Secondary:

Volume:

Pagination:

URL:

Keywords:

Abstract:

Go back to Resources

Studies of a Prophylactic HIV-1 Vaccine Candidate Based on Modified Vaccinia Virus Ankara (MVA) with and without DNA Priming: Effects of Dosage and Route on Safety and Immunogenicity

Go back to Resources

Studies of a Prophylactic HIV-1 Vaccine Candidate Based on Modified Vaccinia Virus Ankara (MVA) with and without DNA Priming: Effects of Dosage and Route on Safety and Immunogenicity

Authors:

Secondary:

Volume:

Pagination:

URL:

Keywords:

Abstract:

Go back to Resources

Second Annual Analysis of the Collaborative Islet Transplant Registry

Go back to Resources

Second Annual Analysis of the Collaborative Islet Transplant Registry

Authors:

Secondary:

Volume:

Pagination:

URL:

Keywords:

Abstract:

Go back to Resources

Safety, Immunogenicity and Efficacy of Modified Vaccinia Ankara (MVA) Against Dryvax Challenge in Vaccinia-Naive and Vaccinia-Immune Individuals

Go back to Resources

Safety, Immunogenicity and Efficacy of Modified Vaccinia Ankara (MVA) Against Dryvax Challenge in Vaccinia-Naive and Vaccinia-Immune Individuals

Authors:

Secondary:

Volume:

Pagination:

URL:

Keywords:

Abstract:

Go back to Resources

Intravitreal Anti-Vascular Endothelial Growth Factor Therapy with Pegaptanib for Advanced Von Hippel-Lindau Disease of the Retina

Go back to Resources

Intravitreal Anti-Vascular Endothelial Growth Factor Therapy with Pegaptanib for Advanced Von Hippel-Lindau Disease of the Retina

Authors:

Secondary:

Volume:

Pagination:

URL:

Keywords:

Abstract:

Go back to Resources

Effects of Long-term Zinc Supplementation on Plasma Thiol Metabolites and Redox Status in Patients With Age-Related Macular Degeneration

Go back to Resources

Effects of Long-term Zinc Supplementation on Plasma Thiol Metabolites and Redox Status in Patients With Age-Related Macular Degeneration

Authors:

Secondary:

Volume:

Pagination:

URL:

Keywords:

Abstract:

Go back to Resources

Effect of the Orally Administered PKC b Inhibitor, Ruboxistaurin, on Visual Acuity in the PKC-DRS2 Study

Go back to Resources

Effect of the Orally Administered PKC b Inhibitor, Ruboxistaurin, on Visual Acuity in the PKC-DRS2 Study

Authors:

Location:

Go back to Resources

Effect of the orally administered PKC b Inhibitor, Ruboxistaurin, on sustained moderate visual loss in the PKC-DRS2 Study

Go back to Resources

Effect of the orally administered PKC b Inhibitor, Ruboxistaurin, on sustained moderate visual loss in the PKC-DRS2 Study

Authors:

Location:

Go back to Resources

Effect of the oral protein kinase C b Inhibitor, Ruboxistaurin, on visual acuity in the PKC-DRS2 Study

Go back to Resources

Effect of the oral protein kinase C b Inhibitor, Ruboxistaurin, on visual acuity in the PKC-DRS2 Study

Authors:

Location:

Go back to Resources

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 161
  • Page 162
  • Page 163
  • Page 164
  • Current page 165
  • Page 166
  • Page 167
  • Page 168
  • Page 169
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to
Emmes Group

Delivering Global Health
Impact Through People,
Science and Technology

Main navigation
  • Company
    • History
    • Leadership
    • Clients and Collaborators
    • By the Numbers
  • Capabilities
    • Emmes - CRO
    • Veridix - Tech & AI
  • Resources
    • Newsroom
    • Blog
  • Careers
  • Contact
    • Locations
    • Contact Us
linkedin X

Copyright ©, The Emmes Company, LLC

Footer
  • Cookie Policy
  • External Privacy Notice
  • FCOI
  • Emmes EU-U.S. Data Privacy Framework
  • Purchasing Terms and Conditions
  • ISO Certification